Prognostic and Predictive Biomarkers of Lung Cancer
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (30 July 2024) | Viewed by 4162
Special Issue Editor
Interests: clinical oncology; lung diseases; metastasis; cancer biology; cancer biomarkers; cancer diagnostics; tumor biology; cancer cell biology; cell signaling; apoptosis
Special Issue Information
Dear Colleagues,
Biomarkers are essential components in diagnosing a disease or pathogenic process, monitoring patients, and provide prognosis for patients. Despite many advances in diagnosis and treatment, lung cancer remains the greatest cause of cancer-related death worldwide. Therefore, reliable biomarkers are needed to guide an optimal treatment sequence for any patient. Predictive and prognostic biomarkers of lung cancer are of significant therapeutic value as well in early detection and follow-up as in advanced diseases.
To date, many predictive and prognostic biomarkers for lung cancer have been proposed. However, only a few of these have achieved significance in clinical practice.
This Special Issue will be focused on Prognostic and Predictive Biomarkers of Lung Cancer, covering a wide variety of possible approaches ranging from biomaterial-based markers, over clinical patient characteristics to imaging.
Dr. Diego Kauffmann-Guerrero
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- personalized medicine
- molecular signatures
- prognosis
- predictive diagnostics
- prognostic diagnostics
- genetic biomarkers
- blood analysis
- liquid biopsy
- imaging, lung cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.